The Latin America, Middle East and Africa Corneal Implants Market should witness market growth of 9.5% CAGR during the forecast period (2023-2029).
The bioengineered porcine construct (BPCDX) is a clear implantable hydrogel, which is made from a dual photochemical and chemical crosslinking since pure collagen is a soft material that is readily broken. BPCDX has improved the prior porcine collagen-based materials, incorporating photochemical crosslinking utilizing UVA-riboflavin crosslinking technique. Using in vitro and in vivo experiments in mice, guinea pigs, and rabbits, the toxicity, biocompatibility, sensitization, carcinogenicity, and irritation of BPCDX were assessed.
Additionally, it went through a series of third-party verified medical device tests that adhered to ISO standards. Strict quality controls were followed during the production of BPCDX in a clean room with good manufacturing practices (GMP) certification. As opposed to previously published bioengineered pig collagen-based cornea and single-crosslinked BPC, BPCDX exhibits higher mechanical properties without sacrificing transparency and transmits visible light similar to the human cornea. Notably, the BPCDX has a far higher stiffness than a prior collagen-based biomaterial tested on people.
The National Commission for Prevention of Blindness in the United Arab Emirates has started putting the nation's "The Right to Sight" strategy into practice, which aims to cut the prevalence of blindness by half by 2020. The Committee, established in September 2006, took a nationwide survey to determine the frequency and causes of infectious eye illnesses like keratoconus and fuchs' dystrophy. The WHO's 2020 Global Initiative for Prevention of Blindness is the foundation for the UAE's Right to Sight plan. The VISION 2020 Global Initiative's goal is to prioritize public health by eradicating the primary causes of preventable and treatable blindness. Therefore, these factors growth opportunities for the corneal implants market in the region.
The Brazil market dominated the LAMEA Corneal Implants Market by Country in 2022, and would continue to be a dominant market till 2029; thereby, achieving a market value of $10.1 million by 2029. The Argentina market is experiencing a CAGR of 10.1% during (2023-2029). Additionally, The UAE market would showcase a CAGR of 9.2% during (2023-2029).
Based on Disease Type, the market is segmented into Fuchs' Dystrophy, Keratoconus, Infectious Keratitis and Others. Based on Procedure Type, the market is segmented into Penetrating Keratoplasty, Endothelial Keratoplasty, and Others. Based on End-user, the market is segmented into Hospitals, Ophthalmic Centers and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Presbia PLC, CorNeat Vision Ltd., Alcon, Inc., AJL Opthalmic SA, LinkoCare Life Sciences AB, CorneaGen, DIOPTEX GmbH, Mediphacos Industrias Medicas S.A., EyeYon Medical Ltd., and KeraMed, Inc.
The bioengineered porcine construct (BPCDX) is a clear implantable hydrogel, which is made from a dual photochemical and chemical crosslinking since pure collagen is a soft material that is readily broken. BPCDX has improved the prior porcine collagen-based materials, incorporating photochemical crosslinking utilizing UVA-riboflavin crosslinking technique. Using in vitro and in vivo experiments in mice, guinea pigs, and rabbits, the toxicity, biocompatibility, sensitization, carcinogenicity, and irritation of BPCDX were assessed.
Additionally, it went through a series of third-party verified medical device tests that adhered to ISO standards. Strict quality controls were followed during the production of BPCDX in a clean room with good manufacturing practices (GMP) certification. As opposed to previously published bioengineered pig collagen-based cornea and single-crosslinked BPC, BPCDX exhibits higher mechanical properties without sacrificing transparency and transmits visible light similar to the human cornea. Notably, the BPCDX has a far higher stiffness than a prior collagen-based biomaterial tested on people.
The National Commission for Prevention of Blindness in the United Arab Emirates has started putting the nation's "The Right to Sight" strategy into practice, which aims to cut the prevalence of blindness by half by 2020. The Committee, established in September 2006, took a nationwide survey to determine the frequency and causes of infectious eye illnesses like keratoconus and fuchs' dystrophy. The WHO's 2020 Global Initiative for Prevention of Blindness is the foundation for the UAE's Right to Sight plan. The VISION 2020 Global Initiative's goal is to prioritize public health by eradicating the primary causes of preventable and treatable blindness. Therefore, these factors growth opportunities for the corneal implants market in the region.
The Brazil market dominated the LAMEA Corneal Implants Market by Country in 2022, and would continue to be a dominant market till 2029; thereby, achieving a market value of $10.1 million by 2029. The Argentina market is experiencing a CAGR of 10.1% during (2023-2029). Additionally, The UAE market would showcase a CAGR of 9.2% during (2023-2029).
Based on Disease Type, the market is segmented into Fuchs' Dystrophy, Keratoconus, Infectious Keratitis and Others. Based on Procedure Type, the market is segmented into Penetrating Keratoplasty, Endothelial Keratoplasty, and Others. Based on End-user, the market is segmented into Hospitals, Ophthalmic Centers and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Presbia PLC, CorNeat Vision Ltd., Alcon, Inc., AJL Opthalmic SA, LinkoCare Life Sciences AB, CorneaGen, DIOPTEX GmbH, Mediphacos Industrias Medicas S.A., EyeYon Medical Ltd., and KeraMed, Inc.
Scope of the Study
By Disease Type
- Fuchs' Dystrophy
- Keratoconus
- Infectious Keratitis
- Others
By Procedure Type
- Penetrating Keratoplasty
- Endothelial Keratoplasty
- Others
By End-user
- Hospitals
- Ophthalmic Centers
- Others
By Country
- Brazil
- Argentina
- UAE
- Egypt
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- Presbia PLC
- CorNeat Vision Ltd.
- Alcon, Inc.
- AJL Opthalmic SA
- LinkoCare Life Sciences AB
- CorneaGen
- DIOPTEX GmbH
- Mediphacos Industrias Medicas S.A.
- EyeYon Medical Ltd.
- KeraMed, Inc.
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 4. LAMEA Corneal Implants Market by Disease Type
Chapter 5. LAMEA Corneal Implants Market by Procedure Type
Chapter 6. LAMEA Corneal Implants Market by End User
Chapter 7. LAMEA Corneal Implants Market by Country
Chapter 8. Company Profiles
Companies Mentioned
- Presbia PLC
- CorNeat Vision Ltd.
- Alcon, Inc.
- AJL Opthalmic SA
- LinkoCare Life Sciences AB
- CorneaGen
- DIOPTEX GmbH
- Mediphacos Industrias Medicas S.A.
- EyeYon Medical Ltd.
- KeraMed, Inc.
Methodology
LOADING...
